Providence Health & Services

06/12/2026 | Press release | Archived content

Advancing cancer care with AI-driven precision

Advancing cancer care with AI-driven precision

June 2026

Through a collaboration between Providence Cancer Institute and Microsoft, patients are benefiting from a groundbreaking artificial intelligence tool called GigaPath. This innovation uses routine pathology images - known as hematoxylin and eosin (H&E) slides - to help identify genetic changes in cancer.

Traditionally, detecting these mutations can require additional testing and time. GigaPath offers a new approach by predicting actionable mutations directly from existing images.

Turning insights into treatment

By identifying mutations earlier, care teams can make more informed decisions about targeted therapies - helping match patients to treatments designed for their specific cancer.

This approach supports more personalized care, giving patients access to therapies that may improve outcomes while reducing delays.

By integrating artificial intelligence into routine clinical workflows, we're helping bring leading-edge innovation directly to the bedside.

Follow us on socials to see more stories from our talented providers and community

Previous Article

How "medical twins" are shaping the future of cancer treatment

The "medical twin" concept allows the successful treatment of one cancer patient to inform the treatment of...

Next Article

Helping patients keep their hair during chemotherapy

Funded by our foundation, our cold capping therapy treatment helps minimize hair loss and gives patients mo...

Providence Health & Services published this content on June 12, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 17, 2026 at 16:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]